» Articles » PMID: 30262558

Anti-HLA Antibodies with Complementary and Synergistic Interaction Geometries Promote Classical Complement Activation on Platelets

Abstract

High titers of HLA antibodies are associated with platelet refractoriness, causing poor platelet increments after transfusions in a subset of patients with HLA antibodies. Currently, we do not know the biological mechanisms that explain the variability in clinical responses in HLA alloimmunized patients receiving platelet transfusions. Previously we showed that a subset of anti-HLA IgG-antibodies induces FcγRIIa-dependent platelet activation and enhanced phagocytosis. Here, we investigated whether anti-HLA IgG can induce complement activation on platelets. We found that a subset of anti-HLA IgG induced complement activation via the classical pathway, causing C4b and C3b deposition and formation of the membrane-attack complex. This resulted in permeabilization of platelet membranes and increased calcium influx. Complement activation also caused enhanced α-granule release, as measured by CD62P surface exposure. Blocking studies revealed that platelet activation was caused by FcγRIIa-dependent signaling as well as HLA antibody induced complement activation. Synergistic complement activation employing combinations of monoclonal IgGs suggested that assembly of oligomeric IgG complexes strongly promoted complement activation through binding of IgGs to different antigenic determinants on HLA. In agreement with this, we observed that preventing anti-HLA-IgG hexamer formation using an IgG-Fc:Fc blocking peptide, completely inhibited C3b and C4b deposition. Our results show that HLA antibodies can induce complement activation on platelets including membrane attack complex formation, pore formation and calcium influx. We propose that these events can contribute to fast platelet clearance in patients refractory to platelet transfusions with HLA alloantibodies, who may benefit from functional-platelet matching and treatment with complement inhibitors.

Citing Articles

Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre.

Li X, Liu Q, Dong J, Hong Y, Xin C, Guo J Ann Med. 2024; 57(1):2446689.

PMID: 39731480 PMC: 11703460. DOI: 10.1080/07853890.2024.2446689.


characterization of rare anti-αβ isoantibodies produced by patients with Glanzmann thrombasthenia that severely block fibrinogen binding and generate procoagulant platelets via complement activation.

Lee C, Huguenin Y, Pillois X, Moulieras M, Marcy E, Whittaker S Res Pract Thromb Haemost. 2024; 8(1):102253.

PMID: 38268518 PMC: 10805943. DOI: 10.1016/j.rpth.2023.102253.


analysis of anti-HPA-1a dependent platelet phagocytosis and its inhibition using a new whole blood phagocytosis assay (WHOPPA).

Ames P, Baal N, Speckmann M, Michel G, Ratke J, Klesser C Front Immunol. 2023; 14:1283704.

PMID: 38077345 PMC: 10702767. DOI: 10.3389/fimmu.2023.1283704.


Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.

Couvidou A, Rojas-Jimenez G, Dupuis A, Maitre B Front Immunol. 2023; 14:1125367.

PMID: 36845153 PMC: 9947338. DOI: 10.3389/fimmu.2023.1125367.


Factors affecting IgG4-mediated complement activation.

Oskam N, Damelang T, Streutker M, Ooijevaar-De Heer P, Nouta J, Koeleman C Front Immunol. 2023; 14:1087532.

PMID: 36776883 PMC: 9910309. DOI: 10.3389/fimmu.2023.1087532.


References
1.
Hickey M, Valenzuela N, Reed E . Alloantibody Generation and Effector Function Following Sensitization to Human Leukocyte Antigen. Front Immunol. 2016; 7:30. PMC: 4740371. DOI: 10.3389/fimmu.2016.00030. View

2.
de Clippel D, Baeten M, Torfs A, Emonds M, Feys H, Compernolle V . Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion. 2014; 54(12):3036-42. DOI: 10.1111/trf.12727. View

3.
Tegla C, Cudrici C, Patel S, Trippe 3rd R, Rus V, Niculescu F . Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res. 2011; 51(1):45-60. PMC: 3732183. DOI: 10.1007/s12026-011-8239-5. View

4.
Dekkers G, Plomp R, Koeleman C, Visser R, von Horsten H, Sandig V . Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans. Sci Rep. 2016; 6:36964. PMC: 5131652. DOI: 10.1038/srep36964. View

5.
Padmanabhan A, Jones C, Pechauer S, Curtis B, Bougie D, Irani M . IVIg for Treatment of Severe Refractory Heparin-Induced Thrombocytopenia. Chest. 2017; 152(3):478-485. PMC: 5812774. DOI: 10.1016/j.chest.2017.03.050. View